Inhibikase Therapeutics: Q2 Earnings Insights



Inhibikase Therapeutics IKT reported its Q2 earnings results on Friday, August 12, 2022 at 04:00 PM.

Here’s what investors need to know about the announcement.


Inhibikase Therapeutics beat estimated earnings by 5.26%, reporting an EPS of $-0.18 versus an estimate of $-0.19.

Revenue was down $1.36 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.01 which was followed by a 1.63% increase in the share price the next day.

Here’s a look at Inhibikase Therapeutics’s past performance:


Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate -0.17 -0.17 -0.14 -0.38
EPS Actual -0.18 -0.20 -0.18 -0.22
Revenue Estimate 300K 300K 328K 300K
Revenue Actual 46K 1.94M 328K 1.36M

To track all earnings releases for Inhibikase Therapeutics visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.


Image and article originally from Read the original article here.